Literature DB >> 24668837

Teicoplanin for treating MRSA pneumonia.

J Mukhopadhyay1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24668837     DOI： 10.1136/bmj.g2317

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

Review 1.  Peptide-Based Vaccines and Therapeutics for COVID-19.

Authors:  Pritam V Bagwe; Priyal V Bagwe; Sai Srinivas Ponugoti; Shreerang V Joshi
Journal:  Int J Pept Res Ther       Date:  2022-04-19       Impact factor: 2.191

Review 2.  Peptide and peptide-based inhibitors of SARS-CoV-2 entry.

Authors:  Desiree Schütz; Yasser B Ruiz-Blanco; Jan Münch; Frank Kirchhoff; Elsa Sanchez-Garcia; Janis A Müller
Journal:  Adv Drug Deliv Rev       Date:  2020-11-13       Impact factor: 15.470

3.  Comparison of mortality and clinical failure rates between vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia.

Authors:  Jang Ho Lee; Myeong Geun Choi; Hyung Jun Park; Ho Cheol Kim; Chang-Min Choi
Journal:  BMC Infect Dis       Date:  2022-07-07       Impact factor: 3.667
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.